Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
Roivant Sciences Ltd's Business Segments
Roivant Sciences Ltd's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of FY
Reportable Segments
1
Largest Segment
Reportable
Total Revenue
$ 1
Regions Reported
-
Revenue Share by Reportable Segment - FY
- Reportable100%
Revenue by Reportable Segment - FY
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 1 | 100% |
Annual Results
Revenue Share by Reportable Segment - FY2025
- Reportable0%
Revenue by Reportable Segment - FY2025
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Reportable | $ 29 | - |
Description of Roivant Sciences Ltd
Roivant Sciences Ltd is a biopharmaceutical company that is focused on improving the way new medicines are discovered, developed, and brought to market. It was founded in 2014 by Vivek Ramaswamy and is headquartered in Basel, Switzerland. The company operates with the mission to reduce the time and cost associated with the development of new therapies.
Roivant Sciences operates on an innovative business model that involves creating subsidiary companies, each dedicated to developing drugs targeting a specific disease area. These subsidiaries are referred to as Vants and are led by experienced management teams.
One of the key driving factors behind Roivant Sciences' approach is the recognition of the significant challenges faced by traditional drug development approaches, such as long development timelines, high costs, and high failure rates. By creating Vants focused on specific therapeutic areas, Roivant aims to streamline the drug development process and increase the chances of success.
Each Vant within Roivant Sciences operates independently, with its own dedicated team of scientists, researchers, and professionals. This allows for a decentralized and nimble approach to drug development, enabling quicker decision-making and resource allocation. The Vants leverage data-driven technologies, advanced analytics, and artificial intelligence to identify and prioritize drug candidates with the highest potential for success.
Roivant Sciences has established numerous Vants across a range of therapeutic areas, including neurology, rare diseases, urology, and dermatology. Some of the well-known Vants include Axovant Sciences, Myovant Sciences, Dermavant Sciences, and Urovant Sciences. Each Vant focuses on developing innovative therapies to address unmet medical needs within their respective therapeutic areas.
In addition to its focus on drug development, Roivant Sciences also invests in building a strong infrastructure to support its subsidiaries. This includes expertise in regulatory affairs, clinical development, commercialization, and other key areas necessary for successful drug development. By centralizing these functions, Roivant Sciences can provide efficient and cost-effective support to its Vants.
Furthermore, Roivant Sciences has also entered into strategic partnerships with other pharmaceutical companies to enhance its drug development capabilities. These partnerships often involve collaborations on clinical trials, research, and development, and can potentially provide access to additional resources and expertise.
Overall, Roivant Sciences Ltd is a pioneering biopharmaceutical company that is revolutionizing the drug discovery and development process. Through its unique business model, decentralized approach, and strategic partnerships, Roivant Sciences is striving to bring innovative therapies to patients faster and at a lower cost, ultimately improving global healthcare outcomes.
Roivant Sciences operates on an innovative business model that involves creating subsidiary companies, each dedicated to developing drugs targeting a specific disease area. These subsidiaries are referred to as Vants and are led by experienced management teams.
One of the key driving factors behind Roivant Sciences' approach is the recognition of the significant challenges faced by traditional drug development approaches, such as long development timelines, high costs, and high failure rates. By creating Vants focused on specific therapeutic areas, Roivant aims to streamline the drug development process and increase the chances of success.
Each Vant within Roivant Sciences operates independently, with its own dedicated team of scientists, researchers, and professionals. This allows for a decentralized and nimble approach to drug development, enabling quicker decision-making and resource allocation. The Vants leverage data-driven technologies, advanced analytics, and artificial intelligence to identify and prioritize drug candidates with the highest potential for success.
Roivant Sciences has established numerous Vants across a range of therapeutic areas, including neurology, rare diseases, urology, and dermatology. Some of the well-known Vants include Axovant Sciences, Myovant Sciences, Dermavant Sciences, and Urovant Sciences. Each Vant focuses on developing innovative therapies to address unmet medical needs within their respective therapeutic areas.
In addition to its focus on drug development, Roivant Sciences also invests in building a strong infrastructure to support its subsidiaries. This includes expertise in regulatory affairs, clinical development, commercialization, and other key areas necessary for successful drug development. By centralizing these functions, Roivant Sciences can provide efficient and cost-effective support to its Vants.
Furthermore, Roivant Sciences has also entered into strategic partnerships with other pharmaceutical companies to enhance its drug development capabilities. These partnerships often involve collaborations on clinical trials, research, and development, and can potentially provide access to additional resources and expertise.
Overall, Roivant Sciences Ltd is a pioneering biopharmaceutical company that is revolutionizing the drug discovery and development process. Through its unique business model, decentralized approach, and strategic partnerships, Roivant Sciences is striving to bring innovative therapies to patients faster and at a lower cost, ultimately improving global healthcare outcomes.
Roivant Sciences Ltd. is a biopharmaceutical company that operates with a unique model focused on developing and commercializing innovative therapies. The company primarily targets diseases that are often overlooked in traditional pharmaceutical research and development. Within its structured organization, Roivant employs a variety of segments, products, and services designed to expedite drug development, maximize therapeutic potential, and enhance patient outcomes.
Segments
Roivant Sciences employs a decentralized operating model that results in several key segments or Vants,each dedicated to developing specific therapeutic areas or drug candidates. This model allows for specialization and agility in addressing unmet medical needs.
1. Therapeutic Areas:
- Neurology: Focused on disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, this segment seeks to create innovative therapies targeting the underlying mechanisms of nervous system diseases.
- Immunology: Concentrates on autoimmune diseases and aims to develop therapies that modulate the immune system to provide relief and long-term efficacy.
- Oncology: Dedicated to cancer treatment, this segment works on targeted therapies and immunotherapies aimed at various cancer types.
- Rare Diseases: This segment targets genetic and rare conditions that have limited treatment options, often employing innovative approaches to find viable solutions.
Products
Roivants product portfolio is diverse, encompassing both clinical and preclinical-stage therapies across its various segments. Some notable products include:
1. Breztri (breztri aerosol): An inhalation solution for chronic obstructive pulmonary disease (COPD) management.
2. Rho (RhoA inhibitor): Targeting cardiovascular diseases, currently in different stages of clinical development.
3. Versius (anti-infective platform): Focused on developing treatments against resistant bacterial infections.
4. Rivanad (anti-inflammatory): A drug candidate aimed at treating conditions linked to chronic inflammation.
In addition to proprietary products, Roivant partners with other pharmaceutical entities to co-develop or license new therapeutics, enhancing their product offerings.
Services
Roivant Sciences also provides several services that support drug development and enhance its operational capacity:
1. Clinical Development Services: Through partnerships or internal resources, Roivant offers expertise in designing, implementing, and managing clinical trials, ensuring compliance and maximizing data integrity.
2. Regulatory Affairs: The company has a talented regulatory team that guides products through the complexities of regulatory submissions, facilitating approval processes with agencies like the FDA.
3. Commercial Strategy Development: Roivant supports its product launches with commercial insights, market access strategies, and patient engagement initiatives designed to maximize market penetration and product uptake.
4. Real-World Evidence (RWE) Programs: Utilizing RWE methodologies, Roivant gathers insights and data from actual patient experiences to inform product development, improve outcomes, and support claims to regulatory bodies.
5. Patient Services and Support Programs: Understanding the patient journey, Roivant invests in programs that bridge the gap between patients and treatments, ensuring access and support for patients during their treatment paths.
By leveraging these segments, products, and services, Roivant Sciences aims to innovate the biopharmaceutical landscape, bringing novel therapies to patients and addressing pressing medical needs with speed and efficiency. The integration of commercial viability with scientific innovation is at the core of Roivants mission, allowing for a patient-centric approach in all its endeavors.
Segments
Roivant Sciences employs a decentralized operating model that results in several key segments or Vants,each dedicated to developing specific therapeutic areas or drug candidates. This model allows for specialization and agility in addressing unmet medical needs.
1. Therapeutic Areas:
- Neurology: Focused on disorders such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis, this segment seeks to create innovative therapies targeting the underlying mechanisms of nervous system diseases.
- Immunology: Concentrates on autoimmune diseases and aims to develop therapies that modulate the immune system to provide relief and long-term efficacy.
- Oncology: Dedicated to cancer treatment, this segment works on targeted therapies and immunotherapies aimed at various cancer types.
- Rare Diseases: This segment targets genetic and rare conditions that have limited treatment options, often employing innovative approaches to find viable solutions.
Products
Roivants product portfolio is diverse, encompassing both clinical and preclinical-stage therapies across its various segments. Some notable products include:
1. Breztri (breztri aerosol): An inhalation solution for chronic obstructive pulmonary disease (COPD) management.
2. Rho (RhoA inhibitor): Targeting cardiovascular diseases, currently in different stages of clinical development.
3. Versius (anti-infective platform): Focused on developing treatments against resistant bacterial infections.
4. Rivanad (anti-inflammatory): A drug candidate aimed at treating conditions linked to chronic inflammation.
In addition to proprietary products, Roivant partners with other pharmaceutical entities to co-develop or license new therapeutics, enhancing their product offerings.
Services
Roivant Sciences also provides several services that support drug development and enhance its operational capacity:
1. Clinical Development Services: Through partnerships or internal resources, Roivant offers expertise in designing, implementing, and managing clinical trials, ensuring compliance and maximizing data integrity.
2. Regulatory Affairs: The company has a talented regulatory team that guides products through the complexities of regulatory submissions, facilitating approval processes with agencies like the FDA.
3. Commercial Strategy Development: Roivant supports its product launches with commercial insights, market access strategies, and patient engagement initiatives designed to maximize market penetration and product uptake.
4. Real-World Evidence (RWE) Programs: Utilizing RWE methodologies, Roivant gathers insights and data from actual patient experiences to inform product development, improve outcomes, and support claims to regulatory bodies.
5. Patient Services and Support Programs: Understanding the patient journey, Roivant invests in programs that bridge the gap between patients and treatments, ensuring access and support for patients during their treatment paths.
By leveraging these segments, products, and services, Roivant Sciences aims to innovate the biopharmaceutical landscape, bringing novel therapies to patients and addressing pressing medical needs with speed and efficiency. The integration of commercial viability with scientific innovation is at the core of Roivants mission, allowing for a patient-centric approach in all its endeavors.